View Financial HealthMedCap 配当と自社株買い配当金 基準チェック /06MedCap配当金を支払った記録がありません。主要情報n/a配当利回り-0.03%バイバック利回り総株主利回り-0.03%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新お知らせ • May 10MedCap AB (publ) (OM:MCAP) announces an Equity Buyback for SEK 26 million worth of its shares.MedCap AB (publ) (OM:MCAP) announces a share repurchase program. Under the program, the company will repurchase up to SEK 26 million worth of its shares. The shares shall be acquired at a price per share within the price range applicable on Nasdaq Stockholm at any time, which refers to the interval between the highest bid price and the lowest ask price published continuously by Nasdaq Stockholm. The purpose of the program is to secure the Company's commitment to share-based incentive programs (LTIP 2025/2028) through holdings of unvested shares and to continuously adapt the Company's capital structure to the Company's capital needs and thereby contribute to increased shareholder value, and to enable future acquisitions of companies or businesses to be made through payment with own shares. The program will be valid till August 29, 2025. As of May 7, 2025, the company had 14,981,353 outstanding shares and 0 treasury shares.すべての更新を表示Recent updatesBuy Or Sell Opportunity • Jun 11Now 20% undervaluedOver the last 90 days, the stock has risen 3.6% to €45.94. The fair value is estimated to be €57.59, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 15% in 2 years. Earnings are forecast to grow by 41% in the next 2 years.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Otto Ankarcrona was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 31MedCap AB (publ), Annual General Meeting, May 04, 2026MedCap AB (publ), Annual General Meeting, May 04, 2026, at 16:00 W. Europe Standard Time. Location: at iva, grev turegatan 16 in stockholm, stockholm Swedenお知らせ • Feb 06MedCap AB (publ) to Report Fiscal Year 2026 Results on Feb 05, 2027MedCap AB (publ) announced that they will report fiscal year 2026 results on Feb 05, 2027お知らせ • Oct 25MedCap AB (publ) to Report Q3, 2026 Results on Oct 23, 2026MedCap AB (publ) announced that they will report Q3, 2026 results on Oct 23, 2026お知らせ • Jul 24+ 2 more updatesMedCap AB (publ) to Report Q1, 2026 Results on Apr 29, 2026MedCap AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026お知らせ • Jun 25MedCap AB (publ) (OM:MCAP) acquired XGX PharmaMedCap AB (publ) (OM:MCAP) agreed to acquire XGX Pharma on June 25, 2025. MedCap AB (publ) (OM:MCAP) completed acquisition of XGX Pharma on June 25, 2025.お知らせ • May 10MedCap AB (publ) (OM:MCAP) announces an Equity Buyback for SEK 26 million worth of its shares.MedCap AB (publ) (OM:MCAP) announces a share repurchase program. Under the program, the company will repurchase up to SEK 26 million worth of its shares. The shares shall be acquired at a price per share within the price range applicable on Nasdaq Stockholm at any time, which refers to the interval between the highest bid price and the lowest ask price published continuously by Nasdaq Stockholm. The purpose of the program is to secure the Company's commitment to share-based incentive programs (LTIP 2025/2028) through holdings of unvested shares and to continuously adapt the Company's capital structure to the Company's capital needs and thereby contribute to increased shareholder value, and to enable future acquisitions of companies or businesses to be made through payment with own shares. The program will be valid till August 29, 2025. As of May 7, 2025, the company had 14,981,353 outstanding shares and 0 treasury shares.お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 05, 2025MedCap AB (publ), Annual General Meeting, May 05, 2025, at 16:00 W. Europe Standard Time. Location: iva, grev turegatan 16, stockholm Swedenお知らせ • Feb 02MedCap AB (publ) to Report Q3, 2025 Results on Oct 24, 2025MedCap AB (publ) announced that they will report Q3, 2025 results on Oct 24, 2025Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: kr3.57 (vs kr2.59 in 3Q 2023)Third quarter 2024 results: EPS: kr3.57 (up from kr2.59 in 3Q 2023). Revenue: kr426.0m (up 17% from 3Q 2023). Net income: kr52.9m (up 38% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €52.00, the stock trades at a trailing P/E ratio of 41.7x. Average trailing P/E is 43x in the Life Sciences industry in Europe. Total returns to shareholders of 146% over the past three years.Reported Earnings • Jul 25Second quarter 2024 earnings released: EPS: kr3.84 (vs kr3.16 in 2Q 2023)Second quarter 2024 results: EPS: kr3.84 (up from kr3.16 in 2Q 2023). Revenue: kr469.9m (up 22% from 2Q 2023). Net income: kr56.8m (up 21% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 32% per year.お知らせ • Jul 25MedCap AB (publ) to Report Q2, 2025 Results on Jul 23, 2025MedCap AB (publ) announced that they will report Q2, 2025 results on Jul 23, 2025New Risk • Jul 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Jul 01Now 17% undervaluedOver the last 90 days, the stock has risen 36% to €44.05. The fair value is estimated to be €53.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.Buy Or Sell Opportunity • Jun 26Now 21% undervaluedOver the last 90 days, the stock has risen 35% to €45.35. The fair value is estimated to be €57.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.お知らせ • May 12MedCap AB (publ) to Report Q1, 2025 Results on Apr 29, 2025MedCap AB (publ) announced that they will report Q1, 2025 results on Apr 29, 2025Reported Earnings • May 03First quarter 2024 earnings released: EPS: kr3.78 (vs kr1.68 in 1Q 2023)First quarter 2024 results: EPS: kr3.78 (up from kr1.68 in 1Q 2023). Revenue: kr463.1m (up 22% from 1Q 2023). Net income: kr56.0m (up 126% from 1Q 2023). Profit margin: 12% (up from 6.5% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 06, 2024MedCap AB (publ), Annual General Meeting, May 06, 2024.お知らせ • Mar 29MedCap AB (publ) to Report Fiscal Year 2024 Results on Jan 31, 2025MedCap AB (publ) announced that they will report fiscal year 2024 results on Jan 31, 2025Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr11.63 (vs kr7.94 in FY 2022)Full year 2023 results: EPS: kr11.63 (up from kr7.94 in FY 2022). Revenue: kr1.60b (up 43% from FY 2022). Net income: kr172.2m (up 46% from FY 2022). Profit margin: 11% (in line with FY 2022).Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €33.10, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 44x in the Life Sciences industry in Europe. Total returns to shareholders of 66% over the past year.お知らせ • Oct 29MedCap AB (publ) to Report Q3, 2024 Results on Oct 25, 2024MedCap AB (publ) announced that they will report Q3, 2024 results on Oct 25, 2024Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: kr2.59 (vs kr2.47 in 3Q 2022)Third quarter 2023 results: EPS: kr2.59 (up from kr2.47 in 3Q 2022). Revenue: kr368.2m (up 52% from 3Q 2022). Net income: kr38.3m (up 4.6% from 3Q 2022). Profit margin: 10% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses.お知らせ • Jul 31MedCap AB (publ) to Report First Half, 2024 Results on Jul 19, 2024MedCap AB (publ) announced that they will report first half, 2024 results on Jul 19, 2024Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: kr3.16 (vs kr1.42 in 2Q 2022)Second quarter 2023 results: EPS: kr3.16 (up from kr1.42 in 2Q 2022). Revenue: kr390.0m (up 37% from 2Q 2022). Net income: kr46.8m (up 123% from 2Q 2022). Profit margin: 12% (up from 7.4% in 2Q 2022). The increase in margin was driven by higher revenue.New Risk • Jul 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Jul 25MedCap AB (publ) (OM:MCAP) signed an agreement to acquire SurgiCube International B.V. for €8 million.MedCap AB (publ) (OM:MCAP) signed an agreement to acquire Surgicube International B.V. for €8 million on July 24, 2023. Under the transaction, MedCap pays €6 million and adjustments for net debt / cash at closing and an earn-out up to €2 million based on the gross profit growth until December 2024. SurgiCube’s sales in the last 12 months amounted to approximately €3.7 million with almost 24% EBITDA-margin. Key individuals in the business have committed to remain as minority owners, and the former majority owner Ger Vijfvinkel has committed to remain as managing director and then as advisor during a transition phase.お知らせ • May 05MedCap AB (publ) to Report Q1, 2024 Results on May 03, 2024MedCap AB (publ) announced that they will report Q1, 2024 results on May 03, 2024Reported Earnings • May 03First quarter 2023 earnings released: EPS: kr1.68 (vs kr1.32 in 1Q 2022)First quarter 2023 results: EPS: kr1.68 (up from kr1.32 in 1Q 2022). Revenue: kr384.0m (up 46% from 1Q 2022). Net income: kr24.8m (up 27% from 1Q 2022). Profit margin: 6.5% (down from 7.5% in 1Q 2022). The decrease in margin was driven by higher expenses.Reported Earnings • Feb 12Full year 2022 earnings released: EPS: kr7.94 (vs kr6.52 in FY 2021)Full year 2022 results: EPS: kr7.94 (up from kr6.52 in FY 2021). Revenue: kr1.15b (up 24% from FY 2021). Net income: kr117.6m (up 22% from FY 2021). Profit margin: 10% (in line with FY 2021).Board Change • Nov 28High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.決済の安定と成長配当データの取得安定した配当: 61MAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 61MAの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場MedCap 配当利回り対市場61MA 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (61MA)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.8%業界平均 (Life Sciences)0.8%アナリスト予想 (61MA) (最長3年)n/a注目すべき配当: 61MAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 61MAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 61MAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 61MAが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/02 11:14終値2026/07/02 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MedCap AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関null nullABG Sundal CollierBjorn RydellABG Sundal Collier SponsoredHans MählerNordea Markets2 その他のアナリストを表示
お知らせ • May 10MedCap AB (publ) (OM:MCAP) announces an Equity Buyback for SEK 26 million worth of its shares.MedCap AB (publ) (OM:MCAP) announces a share repurchase program. Under the program, the company will repurchase up to SEK 26 million worth of its shares. The shares shall be acquired at a price per share within the price range applicable on Nasdaq Stockholm at any time, which refers to the interval between the highest bid price and the lowest ask price published continuously by Nasdaq Stockholm. The purpose of the program is to secure the Company's commitment to share-based incentive programs (LTIP 2025/2028) through holdings of unvested shares and to continuously adapt the Company's capital structure to the Company's capital needs and thereby contribute to increased shareholder value, and to enable future acquisitions of companies or businesses to be made through payment with own shares. The program will be valid till August 29, 2025. As of May 7, 2025, the company had 14,981,353 outstanding shares and 0 treasury shares.
Buy Or Sell Opportunity • Jun 11Now 20% undervaluedOver the last 90 days, the stock has risen 3.6% to €45.94. The fair value is estimated to be €57.59, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 15% in 2 years. Earnings are forecast to grow by 41% in the next 2 years.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Otto Ankarcrona was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 31MedCap AB (publ), Annual General Meeting, May 04, 2026MedCap AB (publ), Annual General Meeting, May 04, 2026, at 16:00 W. Europe Standard Time. Location: at iva, grev turegatan 16 in stockholm, stockholm Sweden
お知らせ • Feb 06MedCap AB (publ) to Report Fiscal Year 2026 Results on Feb 05, 2027MedCap AB (publ) announced that they will report fiscal year 2026 results on Feb 05, 2027
お知らせ • Oct 25MedCap AB (publ) to Report Q3, 2026 Results on Oct 23, 2026MedCap AB (publ) announced that they will report Q3, 2026 results on Oct 23, 2026
お知らせ • Jul 24+ 2 more updatesMedCap AB (publ) to Report Q1, 2026 Results on Apr 29, 2026MedCap AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Jun 25MedCap AB (publ) (OM:MCAP) acquired XGX PharmaMedCap AB (publ) (OM:MCAP) agreed to acquire XGX Pharma on June 25, 2025. MedCap AB (publ) (OM:MCAP) completed acquisition of XGX Pharma on June 25, 2025.
お知らせ • May 10MedCap AB (publ) (OM:MCAP) announces an Equity Buyback for SEK 26 million worth of its shares.MedCap AB (publ) (OM:MCAP) announces a share repurchase program. Under the program, the company will repurchase up to SEK 26 million worth of its shares. The shares shall be acquired at a price per share within the price range applicable on Nasdaq Stockholm at any time, which refers to the interval between the highest bid price and the lowest ask price published continuously by Nasdaq Stockholm. The purpose of the program is to secure the Company's commitment to share-based incentive programs (LTIP 2025/2028) through holdings of unvested shares and to continuously adapt the Company's capital structure to the Company's capital needs and thereby contribute to increased shareholder value, and to enable future acquisitions of companies or businesses to be made through payment with own shares. The program will be valid till August 29, 2025. As of May 7, 2025, the company had 14,981,353 outstanding shares and 0 treasury shares.
お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 05, 2025MedCap AB (publ), Annual General Meeting, May 05, 2025, at 16:00 W. Europe Standard Time. Location: iva, grev turegatan 16, stockholm Sweden
お知らせ • Feb 02MedCap AB (publ) to Report Q3, 2025 Results on Oct 24, 2025MedCap AB (publ) announced that they will report Q3, 2025 results on Oct 24, 2025
Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: kr3.57 (vs kr2.59 in 3Q 2023)Third quarter 2024 results: EPS: kr3.57 (up from kr2.59 in 3Q 2023). Revenue: kr426.0m (up 17% from 3Q 2023). Net income: kr52.9m (up 38% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €52.00, the stock trades at a trailing P/E ratio of 41.7x. Average trailing P/E is 43x in the Life Sciences industry in Europe. Total returns to shareholders of 146% over the past three years.
Reported Earnings • Jul 25Second quarter 2024 earnings released: EPS: kr3.84 (vs kr3.16 in 2Q 2023)Second quarter 2024 results: EPS: kr3.84 (up from kr3.16 in 2Q 2023). Revenue: kr469.9m (up 22% from 2Q 2023). Net income: kr56.8m (up 21% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 32% per year.
お知らせ • Jul 25MedCap AB (publ) to Report Q2, 2025 Results on Jul 23, 2025MedCap AB (publ) announced that they will report Q2, 2025 results on Jul 23, 2025
New Risk • Jul 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Jul 01Now 17% undervaluedOver the last 90 days, the stock has risen 36% to €44.05. The fair value is estimated to be €53.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.
Buy Or Sell Opportunity • Jun 26Now 21% undervaluedOver the last 90 days, the stock has risen 35% to €45.35. The fair value is estimated to be €57.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.
お知らせ • May 12MedCap AB (publ) to Report Q1, 2025 Results on Apr 29, 2025MedCap AB (publ) announced that they will report Q1, 2025 results on Apr 29, 2025
Reported Earnings • May 03First quarter 2024 earnings released: EPS: kr3.78 (vs kr1.68 in 1Q 2023)First quarter 2024 results: EPS: kr3.78 (up from kr1.68 in 1Q 2023). Revenue: kr463.1m (up 22% from 1Q 2023). Net income: kr56.0m (up 126% from 1Q 2023). Profit margin: 12% (up from 6.5% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 06, 2024MedCap AB (publ), Annual General Meeting, May 06, 2024.
お知らせ • Mar 29MedCap AB (publ) to Report Fiscal Year 2024 Results on Jan 31, 2025MedCap AB (publ) announced that they will report fiscal year 2024 results on Jan 31, 2025
Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr11.63 (vs kr7.94 in FY 2022)Full year 2023 results: EPS: kr11.63 (up from kr7.94 in FY 2022). Revenue: kr1.60b (up 43% from FY 2022). Net income: kr172.2m (up 46% from FY 2022). Profit margin: 11% (in line with FY 2022).
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €33.10, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 44x in the Life Sciences industry in Europe. Total returns to shareholders of 66% over the past year.
お知らせ • Oct 29MedCap AB (publ) to Report Q3, 2024 Results on Oct 25, 2024MedCap AB (publ) announced that they will report Q3, 2024 results on Oct 25, 2024
Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: kr2.59 (vs kr2.47 in 3Q 2022)Third quarter 2023 results: EPS: kr2.59 (up from kr2.47 in 3Q 2022). Revenue: kr368.2m (up 52% from 3Q 2022). Net income: kr38.3m (up 4.6% from 3Q 2022). Profit margin: 10% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses.
お知らせ • Jul 31MedCap AB (publ) to Report First Half, 2024 Results on Jul 19, 2024MedCap AB (publ) announced that they will report first half, 2024 results on Jul 19, 2024
Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: kr3.16 (vs kr1.42 in 2Q 2022)Second quarter 2023 results: EPS: kr3.16 (up from kr1.42 in 2Q 2022). Revenue: kr390.0m (up 37% from 2Q 2022). Net income: kr46.8m (up 123% from 2Q 2022). Profit margin: 12% (up from 7.4% in 2Q 2022). The increase in margin was driven by higher revenue.
New Risk • Jul 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Jul 25MedCap AB (publ) (OM:MCAP) signed an agreement to acquire SurgiCube International B.V. for €8 million.MedCap AB (publ) (OM:MCAP) signed an agreement to acquire Surgicube International B.V. for €8 million on July 24, 2023. Under the transaction, MedCap pays €6 million and adjustments for net debt / cash at closing and an earn-out up to €2 million based on the gross profit growth until December 2024. SurgiCube’s sales in the last 12 months amounted to approximately €3.7 million with almost 24% EBITDA-margin. Key individuals in the business have committed to remain as minority owners, and the former majority owner Ger Vijfvinkel has committed to remain as managing director and then as advisor during a transition phase.
お知らせ • May 05MedCap AB (publ) to Report Q1, 2024 Results on May 03, 2024MedCap AB (publ) announced that they will report Q1, 2024 results on May 03, 2024
Reported Earnings • May 03First quarter 2023 earnings released: EPS: kr1.68 (vs kr1.32 in 1Q 2022)First quarter 2023 results: EPS: kr1.68 (up from kr1.32 in 1Q 2022). Revenue: kr384.0m (up 46% from 1Q 2022). Net income: kr24.8m (up 27% from 1Q 2022). Profit margin: 6.5% (down from 7.5% in 1Q 2022). The decrease in margin was driven by higher expenses.
Reported Earnings • Feb 12Full year 2022 earnings released: EPS: kr7.94 (vs kr6.52 in FY 2021)Full year 2022 results: EPS: kr7.94 (up from kr6.52 in FY 2021). Revenue: kr1.15b (up 24% from FY 2021). Net income: kr117.6m (up 22% from FY 2021). Profit margin: 10% (in line with FY 2021).
Board Change • Nov 28High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.